Ramie Tritt

Managing Member at TL Partners

Ramie Tritt

Managing Member at TL Partners

Biography

Ramie A. Tritt, MD is a physician entrepreneur.   On the entrepreneurial side Dr. Tritt co-founded Physician Specialty Corp (PSC), a multi-state physician practice management company in 1996, and was its Chairman and President.  After taking PSC public on Nasdaq in 1997, Dr. Tritt lead the company with rapid growth and annual revenues north of $100 million, and he stayed with the company until 2002 when the company was sold to Allied Capital, a publically traded company based in Washington, DC.   In recognition of these achievements Dr. Tritt was awarded the Ernst & Young Entrepreneur of the Year award in 1999.    Since 2002 his entrepreneurial focus has been on investing in early to mid-stage companies, frequently functioning as an advisor and board member; and over the last ten years Dr. Tritt has also been an active partner in multiple national and international funds which invest in early to mid-stage companies in multiple industries.

Over the past three years Dr. Tritt has been attending cannabis investment meetings and became a lifetime member of the ArcView Group in 2013.   In March 2015 Dr. Tritt became the Founder and Managing Member of TL Partners, LLC, a private investment group, based in Atlanta, GA, which has raised over $2 million dollars for investments in early stage cannabis companies involved in providing ancillary services and products in the cannabis industry.    TL Partners brings both capital and strategic resources to the companies it invests in.   To date TL Partners has invested in 6 companies in the cannabis industry ranging from software, e-commerce, real estate, distribution and a diversified cannabis investment company.  Dr. Tritt is actively involved in the due diligence, deal structure and the follow up investment support with all these companies. On the medical side, Dr. Tritt is meeting with scientists and clinicians involved in cannabis research and patient care, with the goal of introducing disease specific cannabis treatment solutions into the US marketplace.